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Pulmonary Arterial Hypertension (PAH) is a sever disorder characterized by high 
pulmonary artery pressure and pulmonary vascular resistance along with specific histological 
changes. Idiopathic PAH is a human disease of unknown rigin that showed common 
characteristics to PHS/ascites in chicken.  PHS/ascites is a condition found in broilers causing 
right ventricular hypertrophy, valvular insufficiency, increased venous pressure, variable liver 
changes, accumulation of fluids in the abdominal cavity, and finally lung and heart failure. 
Currently, there is no acceptable animal model for human PAH. Our group has been validating 
the chicken as the medical animal model for human PAH, thus we have mapped chromosomal 
regions associated with susceptibility to ascites. The region on Gga9 contains the serotonin 
receptor (5HT2B) gene which showed linkage disequilibrium with respect to ascites 
susceptibility. Sequence data obtained from a previous research work for the 5HT2B gene from 
several SUS and RES lines identified a C/T SNP on the 3rd exon that result in a silent mutation 
and had no effect on protein production or structure. My research project was to extend our 
sequence analysis to the upstream promoter regions of 5HT2B to identify any sequence 
polymorphisms of several DNA samples from both SUS and RES lines. I identified 15 
polymorphisms SNPs present in the 5HT2B promoter region. Three SNPs were found to be in a 
complete linkage defining alternative alleles and have a potential ability in affecting transcription 
factors binding sites. A TaqMan Assay was then developed for these particular SNPs used to 
SNPlotype a large collection of DNA samples from birds previously phenotyped for ascites 
susceptibility in the hypobaric chamber challenged. Statistical analyses of the SNPlotyped data 
support the association of particular genotypes/haploty es of the 5HT2B gene with resistance to 
ascites especially in females. Identifying the underlining genetics of ascites syndrome will lead 
 
 
to genetic selection to reduce ascites incidence in ch cken and further establish chicken as the 
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A. Pulmonary Arterial Hypertension 
Pulmonary Arterial Hypertension (PAH) is a progressive and often a fatal disorder that 
involves high pulmonary artery pressure and pulmonary v scular resistance along with specific 
histological changes. A variety of conditions lead to the increased pressure of pulmonary arteries 
where the arteries are unable to carry enough blood t  the lungs causing cardiac hypertrophy, 
failure of the right ventricle, and premature death (Barst, 2008). Imbalance in the vascular 
mediators that favors excessive proliferation, thromb sis and vasoconstriction (Chapman et al., 
2008) and/or hypoxic conditions can also increase the incidence of PAH (Dempsie; Maclean, 
2008). 
PAH in humans was classified into two classes a primary and secondary pulmonary 
hypertension. Primary Pulmonary Hypertension is now called idiopathic pulmonary arterial 
hypertension (IPAH) due to its unknown etiology where secondary PAH IS known to have 
underlying causes (Barst, 2008; Simmonneau et al., 2004). However, some types of secondary 
PAH are closely similar to IPAH in their histopathology, clinical features and response to 
treatment. Therefore, in 1998 the World Health Organizing (WHO) reclassified the pulmonary 
hypertension into five groups based on the mechanism of the disease rather than associated 
symptoms and conditions. Group 1 is pulmonary arteri l hypertension (PAH) that includes five 
categories: Idiopathic (IPAH), familial (FPAH), associated with risk factors or conditions 
(APAH), persistent pulmonary hypertension of the newborn, and associated with significant 
venous or capillary involvement (Barst, 2008; Simmonneau et al., 2009). 
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IPAH can be defined as having a sustained elevated pulmonary artery pressure of ≥ 25 
mm Hg at rest or ≥ 30 mm Hg during exercise in the absence of other underlying causes such as 
lung or heart diseases (Gaine; Rubin, 1999). In humans, IPAH is a rare disease with an incidence 
of 2-3 per million worldwide per year where the median age at diagnosis is 36 years but it may 
occur at any age. (Rudarakanchana et al., 2001). IPAH is a sporadic disease where a family 
history of PAH or a risk factor can't be recognized. The mean survival after diagnosis is 2.8 
years. (Simonneau et al., 2009; Rudarakanchana et al., 2001). Moreover, the ratio of male to 
female for IPAH in adults is 1: 1.7 (Berger, 2010), which means that females are nearly twice as 
susceptible for IPAH than males. Vascular remodeling in IPAH patients include hypertrophy and 
hyperplasia of smooth muscle cells accompanied by the formation of plexiform lesions in up to 
80% of the cases (Tuder et al., 1994). Plexiform lesions are complex vascular formations 
originated from remodeled pulmonary arteries. Histologically, plexiform lesions are the hall 
mark of IPAH patients especially in advanced stages. In fact, Overbeek et al. have reported that 
10 out of 11 IPAH patients’ lungs had clear evidence of having plexiform lesions (Overbeek et 
al., 2009). When plexogenic arteriopathy obstructs the pulmonary arteries, patients tend to 
become unresponsive to vasodilator therapy with poor r gnosis. There have been studies which 
addressed the linkage of IPAH with the use of anorexigens (appetite suppressant drugs). In the 
1960s, the first link was identified when Primary/Idiopathic PAH was found to be associated 
with the use of anorexigen aminorex fumarate in Switzerland, Austria, and Germany (Kay, 1971; 
Gurtner, 1985). In addition, more cases of IPAH have been linked to the use of fenfluramine 
derivatives in the United Kingdom, France, and Belgium (Douglas, 1981; Delcroix, 1998). The 
increased risk of developing IPAH is associated with the increasing duration of use. 
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The familial form of PAH (FPAH) appears to be inherited as an autosomal dominant trait 
and accounts for about 6% of the total cases of pulmonary arterial hypertension. Moreover, 57% 
of babies born of parents who carry the gene for FPAH were females (Ghamra, 2003; Zemin, 
2000).  In 2000, the gene responsible for FPAH was identified as the Bone Morphogenetic 
Protein Receptor-2 gene (BMPR2), and a correlation has been found between FPAH and 
BMPR2 mutation (Deng; Morse, 2000). Approximately 9% to 26% of the IPAH patients and 
75% of FPAH patients have been detected to have BMPR2 mutations. BMPR2 is a cytokine, a 
member of the transforming growth factor (TGF) - super family, which is important in regulating 
growth, differentiation and apoptosis of numerous types of cells. BMPR2 is essential in 
vasculogenesis and embryonic heart development (Roberts, 2004; Lane et al., 2000). BMPR2 
mutations are likely to be responsible for almost 90% of FPAH.  The mutation likely promotes 
cell division or prevents cell death, resulting in excessive growth of pulmonary arteries 
ultimately leading to arteries narrowed in diameter causing increased resistance to blood flow. 
Surprisingly, only 20% of family members with identified heterozygous BMPR2 mutations 
exhibit PAH phenotype indicating a need for other contributing factors in PAH pathogenesis 
such as environmental, genetic and pathological factors (Launay, 2002; Loyd, 1995; Newman 
JH, 2004) 
Symptoms of PAH are non-specific and include breathl ssness, fatigue, weakness, 
angina, syncope, and abdominal distension. Early diagnosis and treatment for PAH is always 
recommended because late stages of the disease may be less responsive to therapy and mostly 
lead to death (McDonough et al., 2011). Human PAH treatment varies depending on the causes 
of the disease, severity, drug interaction and personal lifestyle. The aim of treatment is to control 
symptoms, prevent more lung damage and slow the progress of the disease. In the last decade, 
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several PAH treatment therapies have been approved that target essential pathways such as 
prostacyclin pathway, nitric oxide pathway, endothelin pathway and serotonin pathway. 
Treatment of PAH patients in advanced therapy include prostanoids, endothelial receptor 
antagonists, phosphodiesterase 5 inhibitors or, rarely, certain calcium channels blockers. 
(Hopkins; Rubin, 2012). A combination of disease spcific-PAH therapies and conventional 
drugs such as diuretics, anticoagulants, oxygen therapy and lung transplantation have improved 
the overall life quality and survival, increased exercise capacity, and reduced symptoms. Several 
studies have found also that these therapies and drugs play an important role in slow growth of 
smooth muscle cells, prevention of blood clots, andincrease in blood and oxygen supply to the 
heart (Barst, 2008; Galie et al., 2004). However, PAH remains a devastating and life- threatening 
disease owing to the low survival rate. 
In the 1960s, the serotonin hypothesis of PAH was first proposed after an outbreak of the 
disease was reported among patients using certain diet pills. Aminorex and fenfluramine are 
appetite suppressant drugs that inhibit serotonin uptake by platelets leading to increased 
extracellular concentration of the serotonin (Rothman et al., 1999). Under hypoxic conditions, 
serotonin is synthesized by tryptophan hydroxylase 1 enzyme (Tph1) and released from 
pulmonary endothelium cells. Serotonin can then influence pulmonary vascular smooth muscle 
proliferation and/or contraction via activity at the serotonin transporter (SERT) and serotonin 
receptors. Intracellular accumulation of serotonin may generates reactive oxygen species (ROS), 
which induce phosphorylation of ERK1/2 MAP kinase. Also, 5HT1B/D receptors activate Rho-
kinase (ROCK).  This enables the translocation of extracellular-regulated kinase (ERK) 1/2 into 
the nucleus. Once Inside the nucleus phosphorylated ERK1/2 can increase transcription of 
nuclear growth factors and mediate cellular proliferation while Rho- kinase activation promotes 
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hypoxic pulmonary vasoconstriction (Lee et al., 1999; Liu et al., 2004; Maclean. M. R, 2007). 
Serotonin (5-hydroxytryptamine, 5-HT) is a pulmonary vasoconstrictor and smooth muscle cell 
mitogen, and it is believed to play a prominent role in the etiology of PAH. In 1990, high levels 
of the plasma 5-HT was reported in patients with platelet storage disease that developed IPAH 
(Herve, et al., 1990). Subsequent experiments reveal d that patients with IPAH have increased 
circulating 5-HT levels even after heart-lung transplantation (Herve, et al., 1995). Additionally, 
cultured pulmonary arterial smooth muscle cells (PASMCS) from pulmonary hypertensive 
patients demonstrate higher proliferative response to 5-HT compared to control subjects. 
Furthermore, isolated endothelial cells and smooth muscle cells from pulmonary arteries of PAH 
patients express mRNAs for 5-HT2A, 5-HT2B and 5-HT1B/D receptors (Launay, 2002; Willers 
et al., 2006). Serotonin induces the proliferation of not only PASMCs, but also pulmonary 
arterial fibroblasts through binding to the 5-HT transporter SERT (welsh et al., 2004; Eddahibi et 
al., 1999). Thus, SERT is believed to be responsible for the mitogenic effects of 5-HT (Willers et 
al., 2006). In contrast, the constricting action of 5-HT on smooth muscle cells is mediated by 5-
HT receptors 5HT2A, 5HT1B/D and 5HT2B (MacLean et al., 2000). However, some research 
groups have shown that the mitogenc responses in pulmonary vascular cell can be achieved by 
using either SERT inhibitors or 5-HT receptor antagonists (Pitt et al., 1994; Welsh et al., 2004). 
This is attributed mainly to cross-talk between SERT and 5-HT receptors to mediate serotonin- 
induced contraction and proliferation of pulmonary tery smooth muscle cells. These vascular 
changes result in the thickening of the medial layer and narrowing the lumen of the pulmonary 
artery leading to the vascular remodeling observed in PAH patients. Moreover, an Indel 
polymorphism was described in the upstream promoter region of the SERT gene with a higher 
frequency of the long (L-type) polymorphism than the short one (S- type) in IPAH patients, 
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which is directly associated with increased SERT expr ssion and activity in platelets and 
PASMCs (Eddahibi et al., 2001). However, SERT genotype neither correlated with age at 
diagnosis, and there was no statistical association with survival interval (Willers et al., 2006). 
Experimentally, mice lacking the 5-HT receptor/transporter gene or carrying mutations in the 5-
HT transporter/receptor or treated with 5-HT transporter/receptor inhibitors were protected 
against hypoxic pulmonary hypertension (McLean M et al., 2000) while introduction of 
exogenous serotonin potentiated the development of hypoxia-induced PAH in rats (Eddahibi et 
al., 1997). Substantial increases in the expression of 5HT2B receptor in pulmonary arteries were 
seen in chronic hypoxic mice. Subsequent treatment with 5HT2B antagonists completely 
prevented the development of the hypoxia induced pulmonary hypertension. Additionally, 
genetic deficiency/mutation of the 5HT2B serotonin receptor reduced the susceptibility towards 
hypoxic PAH in mice (Launay et al., 2002). In this hypoxia-dependent model, elevated 
pulmonary blood pressure and lung remodeling was associated with increased vascular 
proliferation, elastate activity and transforming growth factor- β (TGF- β) levels. These three 
parameters were also found to be potentiated by -Dexfenfluramine- treatment and dependent on 
5HT2B receptor activity (Launay et al., 2002). The 5-HT signaling pathway has been shown to 
play an essential role in PAH and it is believed that by targeting specific components in the 
signaling pathway, investigators can develop some therapeutic strategies that could contribute to 
PAH treatment. 
PAH is a multifactorial polygenic disease which involves the interaction of multiple 
environmental factors, growth factors, receptors, and signaling pathways along with genetic 
influences, all of which can interact with each other in disease development. The National 
Institutes of Health proposed that animal models of pulmonary arterial hypertension are needed 
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to understand the etiology of this disease (Tankson et al., 2001). Currently, there are a number of 
animal models for PAH that has been proposed.  Animals models used commonly include 
chronically hypoxic rats/mice, and the monocrotaline i jected rats. Fawn-hooded rats are known 
to be the most used animal model for PAH in research because they develop more severe forms 
of PAH than other strains following exposure to hypoxia (Stenmark et al., 2009). Other animals 
that have been used as models of PAH are beagle, macaque, calf, rabbit, and piglet (Badyal, 
2003; McMurtry, 2008). At present, there is no perfect animal model for human PAH since no 
animal model reproduces all the clinical histopathological features of human PAH. However, 
using animals as medical models still provides valuable insights into the numerous pathways that 
contribute to the development and the pathogenesis of human PAH. 
B. Pulmonary Hypertension Syndrome/ Ascites 
Ascites, the industrial name for PAH in chicken (also called pulmonary hypertension 
syndrome PHS) is a series of events that affect broiler chickens (meat-type poultry) causing right 
ventricular hypertrophy, valvular insufficiency, increased venous pressure, variable liver 
changes, accumulation of fluids in the abdominal cavity and finally lung and heart failure. In the 
1950s, PHS was first noticed with commercial lines in farms that were located at high altitudes. 
Three decades later PHS in meat- type chickens was associated with a rapid increase in growth 
rate and feed conversion. Increased selection for rapid growth rate leads to increased demands 
for oxygen to keep up with the growing tissues putting more pressure on the pulmonary vascular 
system. However, there are a variety of additional or secondary causes that can increase the 
incidence of PHS (Julian, 1993; Maxwell et al, 1990). Over the years, many environmental and 
management practices have been identified for their ability to trigger ascites in chickens. The 
major environmental cause is hypoxia due to poor ventilation, high altitude and cool 
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temperatures during commercial chicken production. Furthermore, high feed intake, dietary 
energy content, continuous lighting, poor air quality (dust), and genetic selection for mass and 
muscle accumulation for many generations, are the most common management practices that 
increase the incidence of ascites (Julian, 2000). Some studies have shown that some 
microorganisms cause respiratory damage or obstruct he pulmonary airways leading to the 
PHS/ascites development. Gram negative bacteria such as:  Escherichia, Salmonella, and 
Campylobacter, produce a lipopolysaccharide (LPS) which can trigger pulmonary 
vasoconstriction leading to pulmonary hypertension in broiler chickens (Chapman et al., 2005). 
For more than 60 years, broilers have been genetically selected for high body weight and 
meat production to accommodate the increased human population demands. In the 1940s, it took 
about 16 weeks for a broiler chicken to become 2-2.5 Kg in weight. However, by 1990, the 
continued practice of selection improved broiler strains to reach the same market weight within 
43-47 days only (Griffin et al., 1994). In 2001, broilers took only 35 days to reach the same 
weight. Consequently, continued selection for rapid growth improved the meat production and 
increased the poultry industry profits. However, as a result of unnatural rapid growth and heavy 
body weight, broilers are often experiencing skeletal and metabolic disorders including 
PHS/ascites. In addition, broilers possess insufficient vascular capacity that contributes to the 
initiation of PHS. Chicken lungs are relatively small, rigid, and fixed in the thoracic cavity 
compared to mammalian lungs. Moreover, they do not expand and contract with each breath as 
mammals lungs do. Birds rely on the expansion and compression of their air sacs to get air 
through their lungs (Julian, 1993). Normally, the right ventricle pumps only sufficient blood to 
overcome the increased pressure in the lungs. Also, blo d capillaries of the lungs can expand 
only a little to accommodate the increased blood flw (Julian, 1993). 
9 
 
The etiology of PHS in broilers starts with the increased basal metabolic rate and oxygen 
supply required for rapid growth. Any increase in the blood flow because of the demands of the 
fast growing tissues will cause an increase in the blood pressure of the lungs (pulmonary 
hypertension). The right ventricle then will work harder to pump blood to the lungs in response 
to the increasing rate of the blood pressure leading to the thickening of the right ventricle wall 
(Hypotrophy). The cardiac muscles hypertrophy involves proliferation of smooth muscle and 
connective tissues by upregulation of some growth factors. Furthermore, red blood cell 
production increases, to elevate the blood's oxygen carrying capacity. This causes a 'thickening' 
of the blood or increase in the blood viscosity that contributes to the resistance to blood flow. 
Thus, increased pulmonary arterial pressure is a result of both an increase in blood flow and an 
increase in resistance to blood flow. The valves betwe n the right ventricle and the right atrium 
become inefficient and allow some blood to flow back into the atrium as the right ventricle gets 
enlarged and dilated, eventually leading to right ventricular failure. The increase in the blood 
back flow also causes liver congestion (edema) and the high pressure causes the plasma fluids to 
leak out from the liver and the vessels into the body cavity. This results in accumulation of fluid 
in the body cavity; a condition termed “water belly” which is the most apparent sign of ascites 
(Wilson et al., 1988; Julian, 1993; Wideman et al., 2013). 
As mentioned previously with PAH patients, ascitic chickens demonstrate an imbalance 
of vasoactive mediators that favors vasoconstrictors, thromboxane A2 (TxA2), serotonin (5-HT), 
and endothelin-1(ET-1) over vasodilators, nitric oxide (NO), prostacyclin (PGI2), and vascular 
endothelial growth factor (VEGF) etc. Studies have indicated that the key pulmonary vasodilator 
for broilers is (NO) and accumulating evidence revealed that L-arginine, the substrate for (NO) 
production, may be downregulated during PAH/ascites progression (Wideman et al., 2013). In 
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2004, Wideman et al., compared the relative balance between vasoconstrictors and vasodilators 
in broilers challenged by bacterial LPS and found that pulmonary hypertensive responses to LPS 
in broilers were limited when more vasodilators are generated by the animal during LPS 
challenge than vasoconstrictors. Thus, they proposed that innate differences in chemical response 
by the animal during LPS challenge might contribute to differences in susceptibility in broilers 
towered PHS/ascites (Wideman et al., 2004). 
Ascites is a concern for the poultry industry worldwi e because economic losses have 
been estimated to be more than $100 million annually in the US only (Maxwell et al, 1997). 
Ascites affects around 4.7% of living broiler chickens around the world, but the incidence of 
ascites is higher at high altitudes and colder enviro mental temperatures (Wideman, 1988).  
Morbidity usually is 1-5% and the mortality rate is 1-2% which can increase up to 30% at high 
altitude (McMullin, 2004). Development of ascites in chickens has resulted from genetic 
selection for high growth rate and efficient feed conversion to allow the accumulation of body 
mass. Thus, poultry industry and producers must find ways and strategies to eliminate this 
disorder in the near future. There are several management and environmental techniques that can 
be used to reduce the incidence of ascites in chicken for example, improving the air quality and 
ventilation, applying intermittent light and reducing the rapid growth rate (reduce metabolism 
requirements) by applying feed restriction (Balog, 2003). However, all these attempts to reduce 
ascites in chickens have a negative impact on the poultry industry which is not desirable since it 
will slow down the early growth rate of chickens. Genetic selection for ascites resistance could 
reduce this disorder around the world. 
Chicken has been proposed as a preclinical animal model for human IPAH. Although all 
forms of human PAH exhibit arterial changes and vascular remodeling, what appear to 
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distinguish progressive forms of IPAH in humans from all other forms of PAH are the severity of 
the arteriopathy and the formation of plexiform lesion  (Meyrick, 2001). Furthermore, these 
lesions distinguish human IPAH from other animal models, such as the hypertensive dog or 
fawn-hooded rat. Surprisingly, the only animal model of IPAH that spontaneously develops 
lesions which have similar characteristics with those of humans is chicken (Wideman, 2011). 
Methods for induction of PAH in chickens include rapid growth rate, LPS injection, micro-
particle injection, high altitude, poor ventilation, or exposure to hypoxia such as growth in a 
hypobaric chamber. (Chapman et al., 2005, Pavlidis, 2007). Therefore, chicken may be a valid 
medical animal model for genetic and physiological studies of human PAH/IPAH. 
C. Chicken Genome and Chicken Mapping 
In 2004, the International Chicken Genome Sequencing Consortium published the 
genetic sequence of the red jungle fowl (Gallus gallus); the wild ancestor of domestic chicken 
(International Chicken Polymorphism Map Consortium, 2004). Sequence differences were only 
minor between the sequence of the red jungle fowl and the domestic chicken. The chicken’s 
genome is comprised of about 1 billion DNA base pair containing 20,000-23,000 genes. The 
chicken genome is comprised of 38 autosomes, 8 macrochromosomes, 30 microchromosomes, 
and one pair of sex chromosomes. 
Availability of a genome can significantly facilitate mapping of chromosomal regions 
that show association to ascites susceptibility or resistance in chickens. Identification of genes 
associated with ascites will also contribute to thedevelopment of a better treatment and 
understanding for human PAH. There are several genetic markers that can be used for gene 
detection and genotyping such as RFLP (Restriction Fragment Length Polymorphism), VNTR 
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marker (Variable Number Tandem Repeat), STR (Short Tandem Repeat) or microsatellites, and 
SNP (Single Nucleotide Polymorphism). In my research study, I used SNP polymorphism as the 
genetic marker. 
D. Single Nucleotide Polymorphism SNPs 
Single nucleotide polymorphism (SNP) is the genetic variation in the DNA sequence of a 
single nucleotide base (A, G, T or C) between members within the same species or paired 
chromosomes in an individual.  SNPs can be homozygous or heterozygous and can occur within 
coding genes, non-coding regions of genes or in the intr genic regions. SNPs also include one or 
two base insertions/deletions (indels). In humans, 99.9% of the DNA sequence is identical 
between individuals within the same population. The remaining 0.1% is significant because it 
contains approximately 80-90% of all genetic variations as SNPs. This sort of DNA variation 
occurs at a frequent of about 1 every 100-300 bases long the human genome and less frequent 
in the coding regions (Rapley & Harbron 2004; Syvanen, 200). The majority of SNPs convey no 
biological consequence when they occur within the non-coding regions of the DNA or occur as 
synonymous SNPs that cause no change in the amino ac d sequence of a protein. However, a 
fraction of the SNPs have a functional significance and are the key basis of diversity among 
humans (Kwok et al., 2003). SNPs and structural variants were initially discovered by the 
comparison of multiple genomic sequences obtained from different individuals within a 
population. SNP mutation mechanisms include either transitions: purine-purine (A<>G) 
exchange or pyrimidine-pyrimidine (C<>T) exchange, or transversions: purine-
pyrimidine/pyrimidine-purine exchanges (A<>C, A<>T, G<>C, G<>T). In the human genome, 
the ratio of transitions to transversions is approximately 1.7, indicating that transitions occur 
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more frequently along the DNA sequence (Vignal et al., 2002; Kwok et al., 2003). Investigators 
can link a SNP with a phenotype by using Genome-Wide Association Studies (GWAS) where 
hundreds of thousands of SNPs can be scanned per sample. 
As the demand for genetic analysis increases, many approaches and technologies for SNP 
genotyping have been developed. The most popular and simplest one is to perform direct 
sequencing of genomic PCR products from different individuals for a candidate region. The 
major advantages of PCR sequencing are the ability to determine the SNP type, position and the 
sequence context of each polymorphism (Vignal et al., 2002; Kwok et al., 2003). Fluorescently 
tagged PCR primers specific for a particular SNP can be used for sensitive detection of SNPs. 
Subsequent comparison between SNP genotypes to specific phenotype of many individuals 
identify the SNP genotypes that are significantly associated with the phenotype of interest. The 
International Chicken Polymorphism Map Consortium has identified approximately 2.8 million 
single nucleotide polymorphism (SNPs) based on a comparison of the jungle fowl sequence to 
three domestic chicken strains (a broiler, a layer and a Chinese silkie) with a mean rate of about 
five SNPs per kilobase (International Chicken Polymorphism Map Consortium, 2004). 
E. Divergent Selection for Ascites 
Since ascites was first noticed in chickens raised at high altitudes, a simulated high 
altitude environment was the first and simplest technique to select ascites resistant and 
susceptible lines of chickens (Balog, 2003). Dr. Nicholas Anthony, (University ofArkansas, 
Poultry Science) has developed divergently selected susceptible (SUS) and resistant (RES) lines 
of broiler chickens reared in a hypobaric chamber (2,900 m above sea level) to induce the 
disease. The hypobaric chamber simulated high altitude conditions via a partial vacuum, which 
thereby lowered the partial pressure of oxygen. A separate group was reared under typical 
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management and environmental condition, local altitude (390 m above sea level); to serve as the 
control subjects maintained as a randomly mated population (REL line) .The initial generation 
was a commercial elite breeding line obtained from a primary poultry breeding company. Ascites 
mortality data for birds reared in the hypobaric chamber were used for selection of siblings 
reared at ambient pressure. Thus, susceptible and resistant lines were generated based on sibling 
selection over 14 successive generations in the hypobaric chamber. This selection showed an 
average incidence of ascites of 95.1% in the SUS line by the 8th generation, and an average 
incidence of ascites of 7.1% in the RES line by the 9th generation, while the REL line was 
approximately 60% (Pavlidis et al., 2007). 
A cross of the SUS and RES lines was used to generat  an F2 population to map some 
chromosomal regions that have been linked to PAH in humans (Pavlidis et al., 2007). A genome-
wide association study (GWAS) identified 7 chromosomal regions that showed linkage 
disequilibrium with ascites susceptibility and cardi c hypertrophy (Smith, 2009). Further genetic 
analysis confirmed 4 regions on 3 chromosomes that were found to be associated with ascites 
susceptibility. These regions contain candidate genes that might be involved in 
resistance/susceptibility. These genes include AGTR1 (angiotensin 2 type 1 receptor) and 
UTS2D, (urotensin receptor 2 D) located on Gga9:13.5–14.8 Mbp; 5HT2B, (serotonin 
receptor/transporter type 2B) located on Gga9:16 Mbp and ACE (angiotensinogen cleaving 
enzyme) located on Gga27:2 Mbp (Wideman et al., 2013).  All of these genes have been shown 
to be involved in the development of human PAH and they are now under further investigation in 
our lab to determine the extent to which each is involved in ascites/PHS in chicken. My thesis 
work has focused on associations of the 5HT2B gene with ascites. 
F. 5HT2B Receptor 
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The serotonin receptor 5HT2B (also designated HTR2B) is composed of 3 exons located 
at 16.252 Mbp on Gga9 for the 2006 assembly or 14.632 Mbp in the 2011 assembly. In broilers, 
5-HT is the most potent pulmonary vasoconstrictor that triggers pulmonary hypertension 
(Chapman, 2002). The major effect of 5-HT is mediated hrough the receptors/transporter 
(5HT2B) and (5HT1A) on the PASMCs. In chickens, serotonin is released from thrombocytes; 
the equivalent to platelets in humans. It is also released by the pulmonary neuroendocrine 
system. The 5-HT is internalized by the PASMCs causing mooth muscle cells proliferation and 
vascular remodeling (Chapman et al., 2008; Wideman et al., 2013). High levels of 5-HT have 
been induced using various methods such as intravenous micro-particles injection, diets 
containing high levels of Tryptophan (serotonin precursor) or serotonin intra venuous infusion 
(Hamal et al., 2010a; Wideman et al., 2013). Moreover, high expression of 5HT2B receptors in 
the lungs of SUS broilers has been recorded suggestin  their key role pulmonary 
vasoconstriction and PASMC proliferation. However, pretreatment with methiopthepin 
(serotonin receptor blocker) eliminates the increase in pulmonary vascular resistance and reduce 
pulmonary arterial pressure (Hamal et al., 2010a; Wideman et al., 2013).  The evidence is that 
susceptibility to PAH in broilers is partially attributed to the serotonin and serotonin receptors 
overexpression. 
G. The Promoter Region 
The promoter region of a gene is a region that contains specific short DNA sequences 
called transcription factors binding sites where specific transcription factors bind and recruit 
RNA polymerase to the transcription start site. Transcription factors are proteins that positively 
or negatively regulate gene expression through binding to their transcription factor binding sites. 
Sequential assembly of the transcription factors and then RNA Polymerase II forms the pre-
16 
 
initiation complex. Promoter regions can be considere  important molecular tool for the 
regulation of the expression of genes of interest. Typical vertebrate promoters are 100-1000 base 
pairs long located close to and upstream of the genes they transcribe. However, some critical 
sequences may be located further from the transcription start site.  The 5’ proximal region of the 
5HT2B receptor is a critical cis-element that should contain regulatory elements to direct the 
transcription process of a particular gene, and would constitute much of the promoter region.   
Thus, sequence analysis of the 5HT2B promoter regions may identify sequence polymorphisms 
that affect expression of the gene and contribute to ascites. 
Previously in our laboratory, Patrick Greenburg (Honor student, University of Arkansas) 
sequenced the exonic regions of 5HT2B from several DNAs from SUS and RES lines He 
identified 4 SNPs; a SNP in the 5' untranslated region (UTR), one in an intron 2, and two in exon 
3. Exon 3 contains all of the predicted protein coding sequence. The two SNPs in the 3rd exon are 
C/T and C/A SNPs that result in silent mutations, and thus are not likely to affect protein 
production or structure. 
My research project was to extend our sequence analysis to the upstream promoter 
regions of 5HT2B to identify any sequence polymorphisms, especially those affecting predicted 
transcription factor binding sites.  SNPs affecting binding sites would then be analyzed for 
linkage disequilibrium with ascites phenotype. I sequ nced approximately 900 bases of 5’ 
proximal DNA from the RES and SUS lines.  I developd a TaqMan Assays for a particular 
group of SNPs.  This TaqMan assay was then used to SNPlotype a collection of DNA samples 
from birds previously phenotyped for ascites susceptibility in the hypobaric chamber challenged. 
Statistical analysis of the SNPlotyped data helped us etermine the linkage between the different 
alleles and their association with resistance and susceptibility of the chickens to the disease. 
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II MATERIALS AND METHODS 
1. DNA Isolation 
Genomic DNAs were previously isolated from blood from phenotyped birds and stored 
frozen (Krishnamooorthy, 2012). 
2. Primers 
The DNA region for the 5HT2B gene on Gga9 at 16.2 Mbp was downloaded from the UCSC 
genome browser http://genome.ucsc.edu/. Primer3 http://frodo.wi.mit.edu/ was used to design 
PCR primers to cover the promoter region of the gene with lengths of 20-23 base pairs and 
annealing temperature of 50-54oC. Primers were synthesized by Integrated DNA Technologies. 
Primers and probes information are listed in Table 1. 
3. Polymerase Chain Reaction 
PCR was performed using either an MJ Research PTC-100 thermocycler or an Eppendorf 
Mastercycler gradient. PCR mixtures (20 µL) contained: 1X Taq Buffer (50 mMTris-Cl pH 8.3, 
1 mM MgCl2, 30  µg/ml BSA), 0.2 mM dNTPs, 1 µM of reverse and forward primers, 4 units of 
Taq polymerase and 2 µL (approximately 100 ng) of target DNA. PCR amplification conditions 
were initial denaturation at 90°C for 30 seconds, followed by 40 to 45 cycles of denaturation at 
90°C for 20 seconds, 20 seconds of annealing at the indicated temperature (Table 1), and 
elongation at 72°C for 60 seconds, followed by a fin l extension at 72°C for 3 minutes. 
4. Gel Electrophoresis and Gel Imaging 
Following the PCR, 5 µL of purified PCR product was mixed with 5 µL of loading dye 
(20% Ficoll, 2 mM EDTA, and 0.02% Bromophenol Blue) and loaded into a 1.5% agarose gel in 
0.5x TBE buffer (50 mM Tris, 1mM Na2EDTA, ~25 mM Borate pH 8.3) to evaluate PCR 
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products for proper amplification. Gels were stained in ethidium bromide and then either scanned 
at 610 nm on a model 9600 Typhoon Imager (GE Health Care) or imaged using a CCD camera 
and an Ultraviolet transilluminator. Images were analyzed using ImageQuant software. PCR 
fragment sizes were determined using the molecular weight ladder pGEM5 digested with Sau3A 
5. PCR Product Purification and Quantification 
PCR products were purified for sequencing using RapidTi  from Diffinity Genomics 
according to the manufacturer’s instructions. DNAs then were quantified using a TKO 100 
Fluorometer (Hoefer Scientific Instruments) according to the manufacturer’s instructions. 
6. DNA Sequencing and Analysis 
DNA samples were mixed with single primers and submitted for sequencing by the 
University of Arkansas, DNA Resource Center. The sequence files were aligned and analyzed 
using SeqMan software (DNAStar ver 6.0). Specific SNPs in our region of interest were 
identified from the sequence data through comparison to the Jungle Fowl sequence from UCSC. 
7. Real Time PCR- Taqman Assay for SNPlotyping 
A Taqman assay was developed to cover specific SNPs at positions 491, 488, 484 
respectively of the 5HT-2B promoter region (Table 2). The primers and probes are listed in 
Table 1. Real time PCR was performed in 96 well plates using a BioRad CFX 96 Real Time 
System. Reactions (20 µL) were as for standard PCRs (see above with addition of the two probes 
at 0.25 µM. The cycling protocol was: 1) 90°C for 30 seconds, 2) 90°C for 15 seconds, 3) 64°C 
for 30 seconds, 4) repeat steps 2 and 3 for 10 times, 5) 90°C for 15 seconds, 6) 64°C for 30 
seconds + plate read, 7) Repeat steps 5 to 6 for 30 times.  Amplification profiles were visually 
inspected to score for homozygous for either SNP pattern or heterozygous. 
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8. Statistical Analysis 
Genotype data (SNPlotypes) for each sample were compiled and statistically analyzed in 
Microsoft Excel.  Allelic and genotypic frequencies were calculated using observed allele counts. 
Expected allele and genotype frequencies were calculated based on the allele frequencies 
observed in the entire population. Expected genotype counts were also computed based on 
standard Hardy-Weinberg Equilibrium (p2+2pq+q2) to assess whether the assay was performing 
adequately. For each allele and genotype we calculated P- values using the ChiTest in Excel 
comparing the observed counts to the expected counts for the resistant and susceptible 
subpopulations. The level of significant (P<0.05) is the measurement that I used in my study. 
The null hypothesis can be rejected if the significance test gave a P-value lower than (P< 0.05) 
and considered as statistically significant results, and fail to reject the null hypothesis if the 
significance test gave a P-value higher than 0.05 (P> 0.05). 
III. RESULTS 
1. Primer Design, DNA Sequencing and SNP Detection 
For this study, we designed two pairs of oligonucleotide primers 5HT2B PF1/PR1 and 
5HT2B PF2/PR2 respectively to amplify an approximately 900 base region upstream of exon 1 
of the 5HT2B receptor gene located on Gga9. The primer pair names, sequences, fragment sizes, 
annealing and melting temperatures are shown in Table 1. The primers were used to PCR 
amplify the upstream promoter region from DNAs from SUS and RES line birds, and from a 
single White Leghorn male (WL). PCR products were evaluated on agarose gels, purified; 
quantified and submitted for capillary sequencing. The sequences were aligned with the 
sequence for this same region of the 5HT2B receptor gene from the 2006 genome assembly for 
Gallus gallus, the Red Jungle Fowl (JF). The alignments identified 15 polymorphisms (SNPs) in 
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the promoter region of the 5HT2B receptor gene (Table 2). These SNPs are located at different 
distances upstream of the predicted transcription start ite of the 5HT-2B gene (14, 641511bp) 
according to the 2011 chicken assembly (GCA_000002315.2).  
We analyzed the locations of these 15 SNPs for proximity to potential transcription factor 
binding sites. The three SNPs at 484, 488, and 491 were found to affect potential binding sites 
for NF-κB and TonEBP/OREBP transcription factors.  Therefore, polymorphisms for these SNPs 
have the potential to affect gene expression which in turn could contribute to ascites 
susceptibility or resistance.  The SNP found in position 484 was a C/T transition with 
homozygous T in JF, WL and two RES birds, a C in three SUS birds, and heterozygous Y in two 
each of the RES and SUS birds. The rest of the SUS and RES DNA birds for this particular SNP 
could not be determined because of flanking insertion/deletions (indels).  The SNP at position 
488 was an indel with JF, WL and three RES birds homozygous T, three SUS birds were 
homozygous for the deletion, and heterozygotes (designated H in Table 2) were found in three 
RES and six SUS birds. The SNP at position 491 was also an indel with homozygous C in JF, 
WL and three RES birds, homozygous deletion in three SUS birds, and heterozygous H for the 
C/deletion in three RES and six SUS birds (Table 2). Examination of the DNA sequences shows 
that the three SNPs are in complete linkage and thus define two alternative alleles.  Therefore, 
this region was targeted for SNPlotyping for a larger collection of DNA samples.  Two pairs of 
primers were designed to amplify this specific region containing the SNPs located at positions 
484, 488, and 491. The primer pair 5HT2B PF3/PR3 did not amplify a PCR product.  However, 
the primer pair 5HT2B PF4/PR3 produced a PCR product size of 322bp based on evaluation by 
gel electrophoresis (data not shown). 
2. TaqMan Assay for SNP Analysis 
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I developed a TaqMan assay to target this particular group of SNPs for genotype 
determination.  The TaqMan assay provides a fast and simple method to genotype for specific 
SNP patterns in a large number of DNA samples. I design d two specific TaqMan probes for the 
two SNPs patterns with alternative reporter dyes (Table 1). One probe, 5HT-2Btm1 represents 
the JF and WL allele (C-T-T) with HEX as the fluoresc nt reporter dye. The other probe, 5HT-
2Btm2 represents the mutant allele found in SUS and RES birds (_-_-C) with FAM as the 
fluorescent reporter dye. Both probes have a quencher (BQ1) on the 3’ end, so as long as the 
probe remains intact, the quencher reduces the fluorescence emitted by the reporter dye. 
However, once the probe anneals with the specific target DNA sequence, it is digested during the 
extension step of PCR by the Taq polymerase 5’→3’ exonuclease activity. The hydrolysis of the 
probe removes it from the target DNA strand and separates the reporter dye from the quencher, 
allowing detection of the reporter dye fluorescence signal in a real-time PCR machine.  For my 
probes, if the TaqMan assay results in the generation of only the HEX signal, then the individual 
is homozygous wild type at that locus. If the assay results in the generation of only the FAM 
signal, then the individual is homozygous for the alt rnative allele. However, if both fluorescent 
signals are produced, then the individual is heterozyg us.  The TaqMan assay was evaluated at 
different anneal/extension temperatures with DNAs previously sequenced for this region to 
establish optimal temperatures for genotype analyses. 
3. REL Line 
The REL line is the unselected line descended from the original source population for the 
RES and SUS lines.  The TaqMan assay was employed on 192 DNA samples previously 
obtained from birds from generation 14 that had been phenotyped for ascites susceptibility in the 
hypobaric chamber (Sriram Kirshnamoorthy, 2012).  According to the Hardy Weinberg 
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equilibrium, if there are two alleles in a population, with frequencies of p and q, respectively, 
then the values of p and q can be used to calculate exp cted genotype frequencies using the 
formula 1=p2+2pq+q2. 
By analyzing the REL line for the promoter SNPs, two alleles were identified with the 
tm1 allele present at 59% while the tm2 allele was at 41% (Table 3). The observed homozygous 
frequency was relatively high (75%) compared to theexpected frequency (52%) where the 
heterozygous frequency was lower (24%) than expected (48%). The higher number of observed 
homozygous and fewer heterozygous than expected is an indication of the presence of null 
alleles. The presence of null alleles (non-amplified alleles) could lead to false observation of 
excess frequency of homozygotes when segregating with other alleles and fewer heterozygotes 
counts than expected appeared. Thus, it may result in misleading data and cause deviation from 
the Hardy Weinberg equilibrium. A statistical deviation from Hardy Weinberg expectations can 
be detected in the REL line. However, no significant differences from expected genotype 
frequency in respect to ascites phenotype can be detected in this line according to Chi- square 
analyses.  
4. REL vs. RES vs. SUS 
I genotyped samples from 102 RES birds and 59 SUS birds to compare with genotype 
frequencies in the REL.  This analysis was to determine how divergent selection for ascites 
affected allele and genotype frequencies at this locus. Both alleles were detected in all lines. The 
tm1 homozygotes showed similar high frequencies in all the three lines REL, RES and SUS 
(73%, 72%, and 76% respectively).  The tm1/2 heterozyg tes showed similar lower frequencies 
for the respective lines (24%, 26%, and 20% respectively). For the homozygous tm2, the REL, 
RES, and SUS lines had a very low frequency (2%, 1%, and 3% respectively). The 
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tm1homozygotes were found to be more frequent in all three lines.  The tm2 homozygotes were 
found to be at lower frequencies in the three lines as well. Therefore, selection for ascites 
susceptibility or resistance does not appear to have ffected the frequencies of these SNP 
patterns. 
5. Linkage Analysis for Ascites Phenotype in REL 
According to the genotype data in Table 3, the different genotypes were seeing at roughly 
equal frequencies in both SUS and RES birds. At the gender level, the genotypes frequencies 
were approximately the same in both females and males. Chi- square test showed no significant 
deviation from expected allele counts with respect to the two ascites phenotype. Thus, it appears 
that there is no association of the 5HT2B promoter region SNPs with ascites phenotype with 
respect to gender in the REL line.  
6. Haplotype Analysis for the REL Line 
A former honors student, Patrick Greenburg, had sequenced all three exons for 5HT2B 
and identified a C/T SNP (SNP9093) which is 9093 bases downstream of the transcription start 
site and early in the 3rd exon.  The same REL samples had been previously genotyped for that 
SNP.  Chi- square analysis did not detect a statistically significant association of any genotype 
with ascites phenotype.  Table 4 represents allele and genotype data for SNP9093 for the REL 
line.  
We combined the genotype data for SNP9093 and the promoter SNPs (tm1 and tm2) to 
generate haplotypes for the REL line birds (Table 5). The haplotype analysis was to determine 
which SNP9093 allele is in linkage with the tm1 or tm2 allele in the promoter region and 
whether a particular haplotype showed significant li kage disequilibrium (LD) with respect to 
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ascites phenotype.  Surprisingly, we found that SNP9093 and the promoter proximal SNPs show 
a high frequency of recombination despite only being approximately 9500 base pairs separated.  
Whereas we expected to find a high frequency of association of homozygotes for each position 
we instead found that approximately half (74 out of 183) haplotypes were homozygous for one 
SNP position while heterozygous for the other SNP position (haplotypes 12, 21, 23, 32 in Table 
5).  This data suggests an unusually high level of recombination between the two SNP regions 
despite their close proximity.  However, analysis of haplotype with respect to phenotype showed 
that the double heterozygote, 22, is statistically overrepresented in resistant birds (P=0.017).  The 
association was greater in females (P=0.014) than in males (P=0.072).  
7. Promoter SNP Analysis in Commercial Line Y 
Genotype data for samples from commercial line Y identified that the tm1 and tm2 alleles 
appear to represent the major alleles with tm2 allele present at 72% and tm1 28% (Table 6).  The 
genotype data did not deviate from Hardy Weinberg expectations so there do not appears to be 
evidence of additional alleles segregating.  The tm1 homozygotes were overrepresented in 
resistant birds (16:10.9, observed to expected) with frequency of 14%, and underrepresented in 
susceptible birds (2:7.1, observed to expected) with frequency of 2%. Chi-square test showed 
that this difference was statistically significant (P = 0.014) with the deviation only significant in 
females (P=0.001) where all 11 homozygous tm1 femals resistant.  It appears that the 
homozygous tm1 increases resistance to ascites in fmales.  
8. Promoter SNP Analysis of Commercial Line Z 
Analysis of commercial line Z samples for the promoter SNPs identified the tm1 allele at 
43% while the frequency for the tm2 allele was 56% (Table 7).  Hardy Weinberg analysis 
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suggests no evidence for other major alleles in this line.  There was no significant difference 
from expected genotype counts with respect to ascites phenotypes based on Chi-square analyses.  
However, if we compared the observed to the expected counts of resistant and susceptible female 
birds in this population, we found that tm2 homozygous genotype was overrepresented in 
resistant female birds (15:14, observed to expected) an  underrepresented in susceptible female 
birds (6:11.8, observed to expected) but the deviation was not statistically significant (P=0.09).  
Thus, there might be an association to ascites in females for this line but would require analysis 
of additional phenotyped samples.   
9. Promoter SNP Analysis of Commercial Line W 
Analysis of samples from commercial line W for the promoter region SNPs identified the 
tm1 allele was present at 84% compared to the tm2 allele at 16% (Table 8). Hardy Weinberg 
analysis was consistent with these alleles being the predominant alleles in this line.  Chi-square 
analysis of the three genotypes with respect to phenotype detected no significant deviations for 
any genotype with respect to ascites phenotype.  There was also no association of any genotype 
when the line was analyzed separately with respect to gender.  Thus, no strong association to 
ascites can be detected in this line.  
IV. DISCUSSION 
In previous work, 7 chromosomal regions showed linkage disequilibrium with respect to 
ascites susceptibility and cardiac hypertrophy (Smith, 2009).  These regions were identified in 
the whole genome SNP analysis of an F2 cross of the SUS and RES lines. Further genetic 
analysis with microsatellite loci has confirmed theinvolvement of 4 regions on 3 chromosomes 
in ascites susceptibility. The region on Gga9 contains the serotonin receptor (5HT2B) gene 
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located at 16.252 Mbp in the 2006 assembly or 14.632 Mbp in the 2011 assembly. Several 
studies showed that susceptibility to PAH in broilers involves the serotonin pathway or 
metabolism. Moreover, substantial increases in the expression of 5HT2B receptor in pulmonary 
arteries were seen in both human and mice (Launay et al., 2002). For this study, the main 
objective was to identify SNPs present in the promoter region of 5HT2B in SUS and RES line 
birds. Unequal occurrence of several SNPs between the SUS and RES lines could be attributed to 
possible effect of divergent selection for ascites ncidence. Fifteen SNPs were identified with 
SNPs located in close proximity chosen for further analysis owing to their potential to affect 
binding sites for NF-κB and TonEBP/OREBP transcription factors. The three SNPs define two 
alternative alleles and therefore, I developed a TaqMan assay for further analyses of different 
chicken lines.   
 The REL line served as the founder base population for both SUS and RES lines. By 
analyzing the REL line genotypic frequencies, a significant deviation from Hardy Weinberg 
equilibrium was found where higher number of observed homozygous and fewer heterozygous 
than expected were present.  Over representation of homozygotes suggests that we are not 
detecting all alleles for this region and thus null alleles might contribute to the deviation from the
Hardy Weinberg equilibrium. The deviation could also derive from an inaccurate genotyping 
assay or the samples analyzed were not a random sampling of the population. However, the 
possibility of inaccuracy in genotyping performance being responsible for this deviation is not 
supported since we see agreement with Hardy Weinberg in the other lines. Further, the REL line 
samples were for all those challenged in the hypobaric chamber and weren’t selected for any 
specific trait. Thus, there is no evidence that suggests prove that these samples were non-random. 
For this study, we believe that null alleles are most likely responsible for this deviation. Any 
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mutation that affects the DNA sequences specific for either the primers or the probes will 
prevent their hybridization during PCR amplification. Thus, no amplicon is generated or is not 
detected, and this allele would be considered as a null allele. Apparently, undetected alleles for 
this region were segregating with null alleles explains the high frequency of homozygotes. We 
could conclude from this that some of the promoter regions for 5HT2B are actually heterozygous 
but that mutations in either the primer or probe binding sites for one of its two alleles results in a 
null allele and thus it appears as a homozygote. Although null allele heterozygotes are 
undistinguishable from expected homozygotes, direct sequencing for the same region could 
further identify SNPs responsible for the null alleles. Moreover, a possible way to distinguish 
null alleles from any biological processes that might result in deviation from Hardy Weinberg 
equilibrium is by testing candidate genes of REL line for deviation across Gga9.  If this deviation 
occurs only in the 5HT2B gene then we could assume that this deviation is a locus- specific 
phenomenon, possibly null alleles.  
Comparison analyses between the REL, SUS, and RES lines showed the equal 
distribution of the allelic/genotypic frequencies in all three lines indicating that selection for 
ascites susceptibility/resistance had no affect on he respective frequencies. The genotype data 
for SNP9093 located on the 3rd exon of the 5HT2B gene and the promoter SNPs (tm1 and tm2) 
were combined into haplotypes for linkage determinatio . Generated haplotypes gave us an 
informative insight into possible linkage disequilibrium of specific haplotypes to ascites 
phenotype. Haplotype analysis in the REL line revealed an unusually high frequency of 
recombination between SNP90933 and the promoter proximal SNPs despite the short distance 
between the two DNA positions. The high recombination frequency results in individuals that are 
homozygous for SNP9093and heterozygous for the promoter and vice versa. There was almost 
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the same number of haplotypes that were homozygous for 9093SNP and heterozygous for the 
promoter SNPs (27 haplotypes) as for haplotypes that were heterozygous for 9093SNP and 
homozygous for the promoter SNPs (38 haplotypes). We may conclude from this that this 
recombination event could not be a result of null alleles being present in the promoter region 
because if it is true then we should see mostly heterozygotes for SNP9093 that are homozygous 
for the promoter SNPs. One possible approach that would help resolve this would be to conduct 
a pedigree-based study. For future research, it is very important to look at SNP genotyping data 
for this particular region in a large parent- offspring population to detect the segregation patterns 
of the SNPs for exon 3 and the promoter. If we were able to link specific deletion 
variants/polymorphisms to nearby SNPs in the pedigre then we could associate this region to 
ascites. Analysis of haplotype with respect to phenotype showed that the double heterozygote, 
22, haplotype was statistically overrepresented in resistant birds and primarily a female affect. 
Thus, double heterozygote 22 haplotype in REL line showed a significant contribution to ascites 
resistance.  
Commercial broilers represent the product of continuous selection for traits of economic 
importance. The allelic and genotypic frequencies for SNPs present in the 5HT2B promoter 
region were different between the three commercial lines. Probably, the reason behind that is 
differences in selected traits as per the company’s goals. The main objective in analyzing these 
commercial lines was to associate overrepresented genotypes in resistant or susceptible 
phenotypes. In the commercial line Y, the homozygous tm1genotype was highly associated to 
ascites resistant phenotype in females (P= 0.001). Thus, it contributed in increasing resistance to 
ascites in females. Analyzing the commercial line Z showed that the homozygote tm2 genotype 
was overrepresented in females resistant to ascites. However, since no significant deviation was 
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detected by Chi-square analyses, additional phenotyped samples are required to determine 
whether females are strongly associated with ascites resistance or not. In the commercial line W, 
no strong association with ascites was detected. Haplotype analysis of these samples for the 
promoter region and SNP9093 would help us to further search for potential association of the 
5HT2B gene to ascites in this line.  
In summary, our data support the association of particular genotypes/haplotypes of the 
5HT2B gene with resistance to ascites especially in females. The double heterozygote 22 
haplotype and the homozygote tm1 genotype were found to be the most ascites resistant 
haplotype/genotype in the REL and Y line respectively, specially in females. Increasing genetic 
selection for resistant genotypes is a promising tool f r commercial poultry improvement.  Since 
the promoter SNPs affect potential binding sites for transcription factors it will be important to 
examine gene expression levels for the alternative alleles.  Differential expression in particular 
tissues could contribute to ascites susceptibility or resistance. One way to prove the hypothesis is 
by detecting difference in 5HT2B gene expression levels in different pulmonary and arterial 
tissues from resistant and susceptible chickens. Any significant differences in the gene 
expression levels in the two populations can thus be correlated to specific alleles/genotypes in 
this gene. However, genetic selection for ascites resistance could negatively impact traits of 
economic importance like body weight (Pavlidis, 2007). Thus, traditional selection for traits of 
economic importance should go along with selection for ascites resistant genotypes to overcome 
undesirable economic losses. This knowledge of underli ing genetics of ascites syndrome will 
lead to genetic selection to reduce ascites incidene i  chicken and further establish chicken as 
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VI. TABLES AND FIGURES 
 
Table 1.  PCR primers and probes used in this study.  Primer name and sequences (presented as 5’ to 3’ sequence) are listed along 
with their fragment size, Annealing Temperature used, and Calculated Melting Temperature.  For the TaqMan probes the specific 5’ 
and 3’ modifications are listed and the probes are presented in lower case with SNPs indicated in upper case.  Note for indels the SNP 
is missing in the tm2 probe. 
 












HT2B-PR2 GATGATCACCAGCAGGATCAG 50oC 62.6oC 




5HT2B-PF4 GAGGAGGAGTTGCACACACA 54oC 57.2oC 
5HT2Btm1 HEX-tCttTgggTttttcctacagcgg-BQ1 64oC 57.8oC 






Table 2. SNPs identified in the upstream promoter region of HTR2B in selected chicken DNAs.  Sequences w re aligned for DNAs 
from the RES and SUS lines (RES or SUS), White Leghorn (WL) and the published sequence for Jungle Fowl (JF).  SNP positions are 
presented relative to the predicted transcription start ite at 14641511 in the 2011 chicken assembly (GCA_000002315.2).  Question 
mark (?) indicates that the SNP was not determined for that DNA.  Underscore indicates that the base is missing relative to the JF 
reference, and H indicates where an individual was heterozygous for the deleted base.   Standard IUPAC base nomenclature is used 
for heterozygous SNPs. 
Line 
 Distance upstream from Transcription Start Site 1464 511 
 654 642 637 502 494 491 488 484 412 383 341 289 217 123 86 
JF G G C T C C T T A G G A C A T 
WL G G Y Y C C T T A A A _ C G Y 
RES 8465 ? ? ? C C ? T Y M ? ? ? ? ? ? 
RES 8301 ? ? ? T C C T T A G A _ ? ? ? 
RES 8415 G A C T C C T T A G A _ C G T 
RES 8550 ? ? ? Y H H H Y M G A _ ? ? ? 
RES 8553 G G ? Y H H ? ? ? ? ? _ ? ? ? 
RES 8496 R G C Y H H H ? ? ? ? _ C G ? 
SUS 785 G G T C _ _ _ C C G A _ C G T 
SUS 739 G G Y Y H H H Y M G A _ C G T 
SUS 760 G G T C _ _ _ C C G A _ C G T 
SUS 609 R G C Y H H H ? ? ? ? _ ? ? ? 
SUS 789 ? G Y Y H H H ? ? ? ? _ Y G T 
SUS 281 G G Y Y H H H Y M G ? _ C G T 
SUS 852 G G Y Y H H H ? ? ? ? _ C G T 
SUS 907 G G T Y H H H ? ? ? ? _ ? ? ? 





Table 3. Genotype data for the promoter region SNPs for REL line samples.  Genotypes are 
listed in the left most column as tm1= homozygous (_-_-C); tm1/2= heterozygous; tm2= 
homozygous (C-T-T).  Counts, Expected counts, and Frequency are presented for All, resistant 
(Res), and susceptible (Sus) phenotype based on hypobaric chamber challenge.  Counts, 
expected and frequency are also presented for each gender.  Counts for Res and Sus were 












Counts Expected  Frequency Chitest 
All Res Sus Res Sus All Res Sus 
tm1 137 74 45 74.7 43.2 0.733 0.725 0.763 0.777 
tm1/2 45 27 12 24.5 14.2 0.241 0.265 0.203 0.444 
tm2 5 1 2 2.7 1.6 0.027 0.010 0.034 0.272 
Female          
tm1  29 19 29.3 19.0  0.725 0.731 0.954 
tm1/2  11 6 9.6 6.3  0.275 0.231 0.649 
tm2  0 1 1.1 0.7  0.000 0.038 0.273 
Male          
tm1  45 26 45.4 42.2  0.726 0.788 0.707 
tm1/2  16 6 14.9 7.9  0.258 0.182 0.457 




Table 4. Genotype data for SNP9093 (C/T SNP in exon 3) for REL line samples.  Genotypes are 
listed in the left most column.  Columns and headings are as described in Table 3. 
  
All 
Counts Expected Frequency 
chitest 
All Res Sus Res Sus All Res Sus 
C 35 18 11 18.7 11.2 0.19 0.18 0.18 0.858 
Y 58 37 13 31.0 18.6 0.31 0.37 0.22 0.092 
T 94 45 36 50.3 30.2 0.50 0.45 0.60 0.195 
Female 
         
C 
 
7 3 7.9 5.1 
 
0.17 0.11 0.335 
Y 
 
18 7 13.0 8.4 
 
0.43 0.26 0.145 
T 
 
17 17 21.1 13.6 
 
0.40 0.63 0.197 
Male 
         
C 
 
11 8 10.9 6.2 
 
0.19 0.24 0.462 
Y 
 
19 6 18.0 10.2 
 
0.33 0.18 0.179 
T 
 
28 19 29.2 16.6 
 




Table 5: Combined genotype data for haplotype analysis for REL samples.  Haplotype 
designations are 1= homozygous C or tm1; 2= heterozygous; 3= homozygous T or tm2. 
Genotype combinations are listed in the left most clumn with SNP9093 listed first.  Columns 
and headings are as described in Table 3.  
 
All 
Counts Expected Frequency 
Chitest 
All Res Sus Res Sus All Res Sus 
11 32 16 10 17.3 10.1 0.175 0.162 0.172 0.750 
12 3 2 1 1.6 1.0 0.016 0.020 0.017 0.764 
13 0 0 0 0.0 0.0 0.000 0.000 0.000 
 
21 37 23 11 20.0 11.7 0.202 0.232 0.190 0.484 
22 18 14 1 9.7 5.7 0.098 0.141 0.017 0.017 
23 1 0 0 0.5 0.3 0.005 0.000 0.000 0.354 
31 64 32 23 34.6 20.3 0.350 0.323 0.397 0.453 
32 24 11 10 13.0 7.6 0.131 0.111 0.172 0.304 
33 4 1 2 2.2 1.3 0.022 0.010 0.034 0.306 
Female 
         
11 
 
6 2 6.5 4.4 
 
0.162 0.080 0.250 
12 
 
0 1 0.6 0.4 
 
0.000 0.040 0.228 
13 
 






8 6 7.5 5.1 
 
0.216 0.240 0.645 
22 
 
8 1 3.6 2.5 
 
0.216 0.040 0.014 
23 
 
0 0 0.2 0.1 
 
0.000 0.000 0.561 
31 
 
12 10 12.9 8.7 
 
0.324 0.400 0.618 
32 
 
3 4 4.9 3.3 
 
0.081 0.160 0.352 
33 
 
0 1 0.8 0.5 
 
0.000 0.040 0.276 
Male 
         
11 
 
10 8 10.8 5.8 
 
0.161 0.242 0.336 
12 
 
2 0 1.0 0.5 
 
0.032 0.000 0.222 
13 
 






15 5 12.5 6.7 
 
0.242 0.152 0.342 
22 
 
6 0 6.1 3.2 
 
0.097 0.000 0.072 
23 
 
0 0 0.3 0.2 
 
0.000 0.000 0.471 
31 
 
20 13 21.7 11.5 
 
0.323 0.394 0.575 
32 
 
8 6 8.1 4.3 
 
0.129 0.182 0.421 
33 
 
1 1 1.4 0.7 
 






Table 6. Genotype data for promoter region SNPs for commercial line Y (35).  Genotypes, 





Counts Expected Frequency 
chitest 
All Res Sus Res Sus All Res Sus 
tm1 18 16 2 10.9 7.1 0.097 0.142 0.027 0.014 
tm1/2 67 40 27 40.7 26.3 0.360 0.354 0.370 0.860 
tm2 101 57 44 61.4 39.6 0.543 0.504 0.603 0.374 
Female 
         
tm1 
 
11 0 5.0 3.5 
 
0.212 0.000 0.001 
tm1/2 
 
18 13 18.7 13.0 
 
0.346 0.361 0.866 
tm2 
 
23 23 28.2 19.5 
 
0.442 0.639 0.209 
Male 
         
tm1 
 
5 2 5.8 3.5 
 
0.083 0.056 0.388 
tm1/2 
 
21 14 21.6 13.0 
 
0.350 0.389 0.752 
tm2 
 
34 20 32.6 19.5 
 




Table 7. Genotype data for promoter region SNPs for commercial line Z (58).  Genotypes, 




Counts Expected Frequency 
Chitest 
All Res Sus Res Sus All Res Sus 
tm1 37 23 13 24.3 11.9 0.20 0.19 0.20 0.42 
tm1/2 92 58 34 60.4 29.9 0.49 0.47 0.53 0.21 
tm2 60 43 17 39.4 22.2 0.32 0.35 0.27 0.31 
Female 
         
tm1 
 
9 9 8.6 6.3 
 
0.20 0.26 0.28 
tm1/2 
 
20 19 21.4 15.9 
 
0.45 0.56 0.40 
tm2 
 
15 6 14.0 11.8 
 
0.34 0.18 0.09 
Male 
         
tm1 
 
14 4 14.9 5.5 
 
0.18 0.14 0.50 
tm1/2 
 
36 14 37.0 13.6 
 
0.47 0.50 0.85 
tm2 
 
26 10 24.1 8.9 
 




Table 8. Genotype data for promoter region SNPs for commercial line W (74).  Genotypes, 





Counts Expected Frequency 
Chitest 
All Res Sus Res Sus All Res Sus 
tm1 135 68 67 68.2 66.6 0.70 0.70 0.71 0.956 
tm1/2 52 25 27 26.3 24.5 0.27 0.26 0.28 0.572 
tm2 5 4 1 2.5 3.9 0.03 0.04 0.01 0.082 
Female 
         
tm1 
 
34 40 30.9 39.3 
 
0.77 0.71 0.573 
tm1/2 
 
10 15 11.9 14.4 
 
0.23 0.27 0.565 
tm2 
 
0 1 1.1 2.3 
 
0.00 0.02 0.169 
Male 
         
tm1 
 
34 27 37.3 27.4 
 
0.64 0.69 0.589 
tm1/2 
 
15 12 14.4 10.6 
 
0.28 0.31 0.635 
tm2 
 
4 0 1.4 1.0 
 




Figure 1. Genomic region analyzed and location of PCR primers used in this study.  The region of chromosome 9 (2011 Assembly) as 
graphically depicted by the UCSC genome browser presents the negative strand.  Exon 1 is indicated for the HTR2B gene with 
transcription proceeding to the left.  Locations of PCR primers are indicated as black boxes. 
 
 
 
 
